Overview Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma Status: Recruiting Trial end date: 2025-08-10 Target enrollment: Participant gender: Summary To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma. Phase: Phase 2 Details Lead Sponsor: Eye & ENT Hospital of Fudan UniversityCollaborator: Chinese Academy of Medical Sciences